Zolsketil pegylated liposomal

What Zolsketil pegylated liposomal is used for

Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults: • breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease; • advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working; • multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine); • Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin.

Approved use, as published by the European Medicines Agency.

Key facts

Brand

Zolsketil pegylated liposomal

Active substance

doxorubicin

Disease area

Ovarian Neoplasms; Sarcoma, Kaposi; Multiple Myeloma

Medicine group

doxorubicin

ATC code

L01DB01

Marketing authorisation holder

Accord Healthcare S.L.U.

Authorised in the EU since

2022

Official information

• Zolsketil pegylated liposomal: European public assessment report (EPAR), product information and package leaflet, on the EMA website

In India

• Doxorubicin hydrochloride, liposomal: 29 brands in India